These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 25592115)

  • 1. PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.
    Ji M; Liu Y; Li Q; Li XD; Zhao WQ; Zhang H; Zhang X; Jiang JT; Wu CP
    J Transl Med; 2015 Jan; 13():5. PubMed ID: 25592115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
    Meniawy TM; Lake RA; McDonnell AM; Millward MJ; Nowak AK
    Lung Cancer; 2016 Mar; 93():9-16. PubMed ID: 26898608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2014 May; 50(7):1361-9. PubMed ID: 24548766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
    Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
    Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
    Sacher AG; Gandhi L
    JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.
    Tang Y; Fang W; Zhang Y; Hong S; Kang S; Yan Y; Chen N; Zhan J; He X; Qin T; Li G; Tang W; Peng P; Zhang L
    Oncotarget; 2015 Jun; 6(16):14209-19. PubMed ID: 25895031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis.
    Li D; Zhu X; Wang H; Li N
    Eur J Surg Oncol; 2017 Jul; 43(7):1372-1379. PubMed ID: 28259530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
    Ota K; Azuma K; Kawahara A; Hattori S; Iwama E; Tanizaki J; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
    Clin Cancer Res; 2015 Sep; 21(17):4014-21. PubMed ID: 26019170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
    Kerr KM; Nicolson MC
    Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
    Chang YL; Yang CY; Lin MW; Wu CT; Yang PC
    Lung Cancer; 2015 Jun; 88(3):254-9. PubMed ID: 25862146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
    He J; Hu Y; Hu M; Li B
    Sci Rep; 2015 Aug; 5():13110. PubMed ID: 26279307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies.
    Amaya CN; Wians FH; Bryan BA; Torabi A
    Pathology; 2017 Apr; 49(3):292-296. PubMed ID: 28238417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer].
    Zhi X; Li W; Wang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2019 Dec; 22(12):779-785. PubMed ID: 31874674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune-Checkpoint Inhibitors for Lung Cancer with EGFR Mutation].
    Hayashi H; Mitsudomi T
    Gan To Kagaku Ryoho; 2017 Sep; 44(9):722-726. PubMed ID: 28912396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.